Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Monophosphothiamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.98 |
| ▸ | TKT | P29401 | 9/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monophosphothiamine SCHEMBL29733068 | 1.00 | TDP1 (0.98) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL3681710 | 0.99 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL642271 | 0.99 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL17768676 | 0.99 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL9159014 | 0.99 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL23151818 | 0.99 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL399485 | 0.99 | TDP1 (0.96) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL29373566 | 0.99 | TDP1 (1.00) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL94444 | 0.99 | TDP1 (1.00) | TDP1TKTLMNAHSP90AA1ALDH1A1 | |
| Monophosphothiamine SCHEMBL4302184 | 0.98 | TDP1 (0.94) | TDP1TKTLMNAHSP90AA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | REGENERON PHARMA (US) | 2026-04-09 | — | — | US | claimed |
| EP-3889160-B1 | THIAMINE COMPOUND, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION THEREOF | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2026-04-01 | — | — | EP | claimed |
| US-20260041634-A1 | VISCOSITY REDUCING EXCIPIENTS AND COMBINATIONS THEREOF FOR HIGHLY CONCENTRATED NUCLEIC ACID COMPOSITIONS | MERCK PATENT GMBH (DE) | 2026-02-12 | — | — | US | claimed |
| US-20260022411-A1 | MICROBIAL CELL FACTORIES PRODUCING THIAMINE | BIOSYNTIA APS (DK) | 2026-01-22 | — | — | US | claimed |
| US-20250332134-A1 | COMPOSITIONS FOR USE | NESTLE SA (CH) | 2025-10-30 | — | — | US | claimed |
| EP-4608449-A1 | ANTI-C5 ANTIBODY/C5 IRNA CO-FORMULATIONS AND COMBINATION THERAPIES | Regeneron Pharmaceuticals, Inc. (US) | 2025-09-03 | — | — | EP | claimed |
| US-20250228810-A1 | COMPOSITIONS FOR USE | NESTLE SA (CH) | 2025-07-17 | — | — | US | claimed |
| US-20250228809-A1 | COMPOSITIONS FOR USE | NESTLE SA (CH) | 2025-07-17 | — | — | US | claimed |
| WO-2025131987-A1 | VISCOSITY REDUCING EXCIPIENTS AND COMBINATIONS THEREOF FOR LIQUID COMPOSITIONS COMPRISING A PROTEIN | MERCK PATENT GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| US-5681554-A | CONTAINING DIVALENT CATION, HYDROLYZED PROTEIN AND A VITAMIN | COSMAIR, INC. (US) | 1997-10-28 | — | — | US | claimed |
| US-5679697-A | Palladium complexes and methods for using same in the treatment of tumors | GARNETT MCKEEN LABORATORY, INC. | 1997-10-21 | — | — | US | claimed |
| EP-0730449-A1 | NOVEL PALLADIUM COMPLEXES AND METHODS FOR USING SAME IN THE TREATMENT OF TUMORS AND PSORIASIS | Garnett, Merrill (US) | 1996-09-11 | — | — | EP | claimed |
| EP-0385379-B1 | Extractive procedure of thiamine monophosphate from a solution of thiamine phosphates | BASF AG (DE) | 1995-06-21 | — | — | EP | claimed |
| WO-1995014466-A1 | NOVEL PALLADIUM COMPLEXES AND METHODS FOR USING SAME IN THE TREATMENT OF TUMORS AND PSORIASIS | GARNETT MERRILL (US) | 1995-06-01 | — | — | WO | claimed |
| US-5047223-A | Separation of phosphoric acid from aqueous solutions of thiamine phosphates | BASF AKTIENGESELLSCHAFT (DE) | 1991-09-10 | — | — | US | claimed |
| EP-0417953-A1 | Process for producing thiamine phosphates | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-03-20 | — | — | EP | claimed |
| US-4999112-A | Using a Cation Exchanger Resin | BASF AKTIENGESELLSCHAFT (DE) | 1991-03-12 | — | — | US | claimed |
| EP-0385379-A1 | Extractive procedure of thiamine monophosphate from a solution of thiamine phosphates | BASF Aktiengesellschaft (DE) | 1990-09-05 | — | — | EP | claimed |
| US-4717663-A | XANTHOMONAS, CULTURES, AEROBIC, PANTOTHENIC ACID AND/OR THIAMINE (DERIVATIVE) | THE NISSHIN OIL MILLS, LTD. (JP) | 1988-01-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097063-A1 | ANTI-C5 ANTIBODY/C5 IRNA DOSING REGIMENS FOR TREATING C5-ASSOCIATED DISEASES | LDLR, CHRNG, FCGR2A | TDP1 3420/4885TKT 4192/4885LMNA 316/4885 |
| US-20260022411-A1 | MICROBIAL CELL FACTORIES PRODUCING THIAMINE | AHCY, SHMT1, MTHFD1 | TDP1 1224/4885TKT 22/4885LMNA 4260/4885 |
| US-20260041634-A1 | VISCOSITY REDUCING EXCIPIENTS AND COMBINATIONS THEREOF FOR HIGHLY CONCENTRATED NUCLEIC ACID COMPOSITIONS | TYMS, MTHFD1, TYMP | TDP1 12/4885TKT 169/4885LMNA 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.